GILEAD | Medical Information

Epclusa® (sofosbuvir/velpatasvir) Coadministration With H2 Receptor Antagonists

This document is in response to your request for information regarding the coadministration of Epclusa® (sofosbuvir/velpatasvir [SOF/VEL]) with histamine-2 receptor antagonists (H2RAs).

Some data may be outside of the US FDA-approved prescribing information. In providing this data, Gilead Sciences, Inc. is not making any representation as to its clinical relevance or to the use of any Gilead product(s). For information about the approved conditions of use of any Gilead drug product, please consult the FDA-approved prescribing information.

The full indication, important safety information, and boxed warnings are available at: www.gilead.com/-/media/files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.

Product Labeling[1]

Drug Interactions

Established and potentially significant drug interactions

VEL solubility decreases as pH increases. Drugs that increase gastric pH are expected to decrease concentration of VEL.

In drug interaction studies conducted among healthy adults, concomitant administration of H2RA with SOF/VEL decreases the concentration of VEL. H2RAs may be administered simultaneously with or 12 hours apart from SOF/VEL at a dose that does not exceed doses comparable to FAM 40 mg twice daily.

Clinical Data on Coadministration of SOF/VEL With H2RAs

Gilead Phase 1 PK Data

Study design and demographics

Three open-label, randomized, multi-dose, crossover studies evaluated the effect of an H2RA (FAM 40 mg) on the PK parameters of SOF/VEL in healthy volunteers. PK samples of SOF, GS-331007 (SOF metabolite), and VEL were obtained at steady state over a 72-hour period.[2,3]

Results

There were no significant changes in the PK of SOF, GS-331007, or VEL when FAM was either coadministered with SOF/VEL or given 12 hours before SOF/VEL (Table 1).[2,3]

Table 1. PK Parameters of SOF, GS-331007, and VEL + FAM 40 mg (Mogalian et al)[3]

Treatment	SOF or VEL	AUC	C_{max}
SOF/VEL (fasted) with simultaneous FAM 40 mg	SOF	↔	↔
	GS-331007	↔	↔
	VEL	↔	↔
SOF/VEL (fasted) 12 hours after FAM 40 mg	SOF	↔	↓23%
	GS-331007	↔	↔
	VEL	↔	↔

References

1. Enclosed. Gilead Sciences Inc, EPCLUSA® (sofosbuvir and velpatasvir) tablets, for oral use. US Prescribing Information. Foster City, CA.
2. Mogalian E, Lutz J, Osinusi A, et al. Effect of Food and Acid-Reducing Agents on the Relative Bioavailability and Pharmacokinetics of Sofosbuvir/Velpatasvir Fixed-Dose Combination Tablet [Poster PI-050]. Paper presented at: American Society for Clinical Pharmacology and Therapeutics (ASCPT); 08-12 March, 2016; San Diego, CA.
3. Mogalian E, Shen G, Moorehead L, et al. Drug-Drug Interaction Profile of Sofosbuvir/Velpatasvir Fixed-Dose Combination [Poster FRI-168]. Paper presented at: European Association for the Study of the Liver (EASL); 13-17 April, 2016; Barcelona, Spain.

Abbreviations

AUC=area under the curve
C_{max}=maximum plasma concentration
FAM=famotidine
GS-331007=the predominant circulating metabolite of SOF
H2RA=H2-receptor antagonist
PK=pharmacokinetic
SOF=sofosbuvir
VEL=velpatasvir

Product Label

For the full indication, important safety information, and boxed warning(s), please refer to the Epclusa US Prescribing Information available at: www.gilead.com/-/media/files/pdfs/medicines/liver-disease/epclusa/epclusa_pi.

Follow-Up

For any additional questions, please contact Gilead Medical Information at:

☎1-866-MEDI-GSI (1-866-633-4474) or www.askgileadmedical.com

Adverse Event Reporting

Please report all adverse events to:

Gilead Global Patient Safety ☎ 1-800-445-3235, option 3 or www.gilead.com/utility/contact/report-an-adverse-event

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or www.accessdata.fda.gov/scripts/medwatch

Data Privacy

The Medical Information service at Gilead Sciences may collect, store, and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers, and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy-statements) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact privacy@gilead.com.